AbbVie Inc. (ABBV) Stock AnalysisABBVStock AnalysisAbbVie Inc.

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AbbVie Inc is a good buy right now due to its recent positive developments and strong financial indicators. The current price is $255.48, and the company has a forward P/E ratio of 18.69, indicating a reasonable valuation compared to its earnings potential. Additionally, AbbVie has raised its dividends for 54 consecutive years, with a recent payout of $1.73 per share, yielding 2.6%, which is attractive for long-term investors. However, the RSI is currently at 38.91, suggesting that the stock is approaching oversold territory, which could present a buying opportunity.

20 analysts cover ABBV: 10 rate it Buy, 10 Hold and 0 Sell. The average price target is 252.00.